$BOT | #Botanix is pleased to be featured in Dr Boreham’s Crucible. The column includes in-depth look at Botanix and an update on the launch of Sofdra™ (sofpironium) gel, 12.45%. Read the full report: bit.ly/BOT-Biotech-Da… #biotech #dermatology #hyperhidrosis #Sofdra #invest

REGISTER NOW | Join our team for a Sofdra™ Launch Update Webinar on Tuesday 8 July 9:30am AEST / 7:30am AWST for a look at the strong initial performance of Sofdra. Click to pre-register: bit.ly/BOT-Sofdra-Lau…. $BOT #ASX #dermatology #pharma #innovation #hyperhidrosis #launch

REGISTER NOW | Join company executives for our Quarterly Activity and 4c Cash Flow Webinar, Monday 28 July 9:00 am AEST / 7:00 am AWST - an important update. Pre-register: bit.ly/BOT-QuarterlyU… $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis

$BOT released their Quarterly Reports for Q4. The company raised A$40m capital, established a loan facility of up to US$30 million, and had A$64.9m cash at 30 June. Botanix is well funded to support Sofdra™ through to profitability. View Reports: bit.ly/BOT-Quarterly-…

$BOT CEO Dr Howie McKibbon will present at the Canaccord Genuity Annual Growth Conference, which attracts institutional investors and features promising global growth companies, including those in healthcare. View Release bit.ly/BOT-Canaccord #ASX #dermatology #hyperhidrosis

$BOT welcomes Dr Patricia Walker to the Board. She brings experience on boards of leading dermatology companies and a working dermatologist's insights. She led drug development for many key dermatology products, including Sofdra™ (sofpironium). bit.ly/BOT-Patricia-W…

$BOT Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million in cash and $15.3 million in undrawn debt. Operating costs are stable, and revenue is expected to increase quarterly. Botanix is well funded to achieve profitability. bit.ly/BOT_Annual_Rep…

Executive Chairman Vince Ippolito will present on behalf of Botanix at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US) on 9 September at 2–2.30 am AEST. View ASX Release & Presentation: bit.ly/BOT_HCWainwrig… $BOT #ASX #dermatology #hyperhidrosis

REGISTER NOW | Join company executives for our Quarterly Activity and 4C Quarterly Cash Flow Webinar, Monday 20 October at 11.00 am AEDT / 8.00 am AWST for an important update. Pre-register: bit.ly/4nNbYf7 $BOT #dermatology #pharma #biotech #innovation #hyperhidrosis

$BOT released their Quarterly Reports for Q1 FY2026. Quarter over quarter, total prescriptions for Sofdra® (sofpironium) grew 50% as operating cash outflows dropped by 54%. Net revenue was $7.1m. View Reports: bit.ly/4onaUOU #dermatology #pharmaceuticals #pharma #biotech

$BOT CEO Dr Howie McKibbon will present at today’s Canaccord Drug and Device Conference in Noosa, followed by an investor roadshow hosted by Canaccord. View ASX Release: bit.ly/4ot1NfF $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis

$BOT released Q2 Quarterly Reports. Compared to Q1, total prescriptions for Sofdra® grew 24% to 25,351, and net revenue increased 28% to $9.1 million. Read the reports here: bit.ly/4qH4jAp $BOT #ASX #dermatology #pharmaceuticals#pharma #biotech#innovation #hyperhidrosis